TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28699390

Group type: EXPERIMENTAL
Intervention: Classic inspired Valsalva (group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Classic expired Valsalva (group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Balloon-inspired Valsalva (group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Balloon-expired Valsalva (group D)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Combined classic Valsalva (groups A and B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study: 25867274

Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by anastrozole
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) after breast conservation therapy (BCT)
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Breast conservation surgery (BCT) and mastectomy (MX)
Number of subjects: 1324
Study: 23786655

Group type: EXPERIMENTAL
Intervention: Vasopressin (VP) 0.01 to 0.03 U/min
Number of subjects: 121

Group type: COMPARATOR
Intervention: Norepinephrine (NE) 5 to 15 μg/min
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Vasopressin (VP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 121
Study: 22042725

Group type: EXPERIMENTAL
Intervention: Exercise programmes
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Native English speakers
Number of subjects: 270
Study: 19287305

Group type: EXPERIMENTAL
Intervention: multiple hepatic arterial injections of Ad‐p53 (1x10 viral particles) and 5‐FU (500‐750 mg), after TACE
Number of subjects: 46

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 46
Study: 17885005

Group type: EXPERIMENTAL
Intervention: Soymilk (28.51 mg isoflavone aglycone equivalents/portion)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Soy germ (37.99 mg isoflavone aglycone equivalents/portion)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Strong equol producer phenotype
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher PUFA intake
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher alcohol intake
Number of subjects: 100
Study: 15166881

Group type: EXPERIMENTAL
Intervention: Thallium-201 SPECT with attenuation correction (ATC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Thallium-201 SPECT without attenuation correction (non-ATC)
Number of subjects: 39
Study: 12445377

Group type: EXPERIMENTAL
Intervention: Adjuvant CPT-11 after cryosurgery
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Hepatic FUDR after cryosurgery
Number of subjects: 153

Group type: COMPARATOR
Intervention: Cryosurgery alone
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Overall survival from diagnosis of liver metastases
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Overall survival from time of CSA
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Second CSA
Number of subjects: 153
Study: 9704757

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 44
Study: 8034812

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (16 sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 47
Study: 2564458

Group type: EXPERIMENTAL
Intervention: Long-term interferon therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Withdrawal of interferon
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resumption of interferon therapy
Number of subjects: 31
Study: 30426268

Group type: EXPERIMENTAL
Intervention: Rebamipide 2%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rebamipide 4%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28571727

Group type: EXPERIMENTAL
Intervention: Mentha pulegium extract (330mg three times daily for 2 months)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mentha pulegium extract
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26194565

Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT, 9.8 ± 0.1 h time in bed)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Habitual sleep (HAB, 8.2 ± 0.1 h time in bed)
Number of subjects: 14
Study: 22959603

Group type: EXPERIMENTAL
Intervention: PRO‐SELF Plus Pain Control Program (6 visits and 4 phone calls over 10 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard education and care (control group)
Number of subjects: 39
Study: 22303583

Group type: EXPERIMENTAL
Intervention: 100 mg kg‐1 nettle extract, three portions a day for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, three portions a day for 8 weeks
Number of subjects: 50
Study: 19190859

Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 2769

Group type: COMPARATOR
Intervention: Bare Metal Stent (BMS)
Number of subjects: 2769
Study: 16409198

Group type: EXPERIMENTAL
Intervention: Active treatment (latex immunotherapy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12654431

Group type: COMPARATOR
Intervention: Conventional RT
Number of subjects: 926

Group type: COMPARATOR
Intervention: Conventional RT and adjuvant chemotherapy
Number of subjects: 926

Group type: COMPARATOR
Intervention: Conventional RT plus concurrent chemotherapy
Number of subjects: 926

Group type: COMPARATOR
Intervention: Conventional RT plus concurrent chemotherapy and adjuvant chemotherapy
Number of subjects: 926
Study: 11140556

Group type: EXPERIMENTAL
Intervention: Adjunctive systemic doxycycline (200 mg the 1st day, then 100 mg per day for 21 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 39
Study: 9127062

Group type: EXPERIMENTAL
Intervention: Classroom-as-clinic format (n = 45)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Non-classroom-as-clinic format (n = 82)
Number of subjects: 127
Study: 1441695

Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg bid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3548207

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg/day for two days followed by 20 mg/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Mefenamic acid 500 mg t.i.d.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Diclofenac 50 mg b.i.d.
Number of subjects: 91
Study: 30486723

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3,000 pulses each; pressure: 1.8‐2.0 bar; frequency: 10 Hz, once a week for 8 weeks.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combination of an α‐blocker and an anti‐inflammatory agent, treated for 8 weeks.
Number of subjects: 45
Study: 29350481

Group type: EXPERIMENTAL
Intervention: Reassurance
Number of subjects: 73

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 73

Group type: COMPARATOR
Intervention: Reappraisal
Number of subjects: 73
Study: 26840637

Group type: EXPERIMENTAL
Intervention: Routine weighing at each antenatal visit with counselling according to IOM guidelines
Number of subjects: 782

Group type: COMPARATOR
Intervention: Standard antenatal care (recording weight at booking and then at 36 weeks)
Number of subjects: 782
Study: 24762108

Group type: EXPERIMENTAL
Intervention: TAK-448 (0.01-6 mg/d; single-bolus or 2-hour infusion)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: TAK-448 (0.01-1 mg/d; 14-day sc administration)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: TAK-448 (12 or 24 mg sc-depot injections)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: TAK-448 (24 mg sc-depot injections)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 22549752

Group type: EXPERIMENTAL
Intervention: Mesorectal-LN group
Number of subjects: 11567

Group type: COMPARATOR
Intervention: Internal-LPLN group
Number of subjects: 11567

Group type: COMPARATOR
Intervention: N2b group
Number of subjects: 11567

Group type: EXPERIMENTAL
Intervention: External-LPLN group
Number of subjects: 11567
Study: 20548010

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (11 individual and 11 group counseling sessions with a dietitian, 22 physical activity group sessions per year)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Moderate lifestyle intervention (3 individual and 2 group dietary counseling sessions per year, no guided physical activity)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Moderate lifestyle intervention
Number of subjects: 201
Study: 17208597

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin twice daily
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin twice daily
Number of subjects: 137
Study: 14991499

Group type: EXPERIMENTAL
Intervention: Diathermy excision hemorrhoidectomy (Group A, n = 25)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diathermy coagulation (Group B, n = 20)
Number of subjects: 45
Study: 12471296

Group type: EXPERIMENTAL
Intervention: High-volume rope jumping (10 min)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-volume rope jumping (5 min)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study: 9803800

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine kinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MB isoform
Number of subjects: 0
Study: 8582195

Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined or opposed hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feasibility studies
Number of subjects: 0
Study: 1978546

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study: 686354

Group type: EXPERIMENTAL
Intervention: Carticaine 1%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%
Number of subjects: 14
Study: 31831270

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham (touching points within 1 cm of main points)
Number of subjects: 50
Study: 31169862

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 346
Study: 28346568

Group type: EXPERIMENTAL
Intervention: 3-monthly oral doses of 3 mg calcifediol plus daily exercise
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo with standard health recommendations
Number of subjects: 675
Study: 25996764

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intrathecal placebo
Number of subjects: 32
Study: 22840893

Group type: EXPERIMENTAL
Intervention: Visual information with circular path
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual information with figure-eight path
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proprioceptive information with circular path
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proprioceptive information with figure-eight path
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual information
Number of subjects: 40

Group type: COMPARATOR
Intervention: Proprioceptive information
Number of subjects: 40
Study: 21823415

Group type: EXPERIMENTAL
Intervention: Back‐shu point needling
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Back‐shu point needling and trunk exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 90
Study: 19243724

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage therapy (MLDT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Connective tissue massage (CTM)
Number of subjects: 50
Study: 16045516

Group type: COMPARATOR
Intervention: Routine antenatal education
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Additional single educational group session supervised by a lactation specialist
Number of subjects: 1312
Study: 11847955

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 4800000
Study: 10515308

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine (low-dose group)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine (high-dose group)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7733124

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg/d for the first month; thereafter, 400 mg/d for 2 weeks of every 3-month period), elemental calcium (1 g/d), and ergocalciferol (0.5 mg/wk)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Calcium supplements only (1 g/d)
Number of subjects: 26
Study: 1914367

Group type: EXPERIMENTAL
Intervention: 5 mg sibutramine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 20 mg sibutramine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7017991

Group type: EXPERIMENTAL
Intervention: 750 mg/day of chenodeoxycholic acid (CDCA) for 4 months, followed by an additional 4 months for those showing a 25% or more decrease in stone size.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo for 4 months, followed by CDCA for those who initially received placebo.
Number of subjects: 13
Study: 31912632

Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg, subcutaneous, biweekly for 6 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30321476

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU/day)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study: 28382813

Group type: EXPERIMENTAL
Intervention: Aquatic physical training (APT) program, held twice a week for 16 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Aquatic physical training (APT) program
Number of subjects: 54
Study: 25500940

Group type: EXPERIMENTAL
Intervention: Anaesthetist-directed fluid therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pulse-contour-guided fluid optimization strategy using colloid (Gelofusine) boluses
Number of subjects: 130

Group type: COMPARATOR
Intervention: Meta-analysis of four studies
Number of subjects: 130
Study: 23336505

Group type: EXPERIMENTAL
Intervention: JZQG (Jiangzhuoqinggan)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 240
Study: 21626265

Group type: EXPERIMENTAL
Intervention: Medical source seekers (including physicians)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Non-seekers
Number of subjects: 268

Group type: COMPARATOR
Intervention: Non-medical source seekers
Number of subjects: 268
Study: 18929355

Group type: EXPERIMENTAL
Intervention: Lateral approach to the common femoral artery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct approach to the common femoral artery
Number of subjects: 0
Study: 17380681

Group type: EXPERIMENTAL
Intervention: Glide Scope video‐laryngoscope (GSVL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope (FOB)
Number of subjects: 60
Study: 15207410

Group type: EXPERIMENTAL
Intervention: Nicergoline
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 3000
Study: 11589865

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (30 microg weekly intramuscular injections)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 9532999

Group type: EXPERIMENTAL
Intervention: Catheter-tip transducers tied together and introduced transcervically into the uterine cavity after delivery of the placenta
Number of subjects: 20

Group type: COMPARATOR
Intervention: Catheter-tip transducers inserted independently into the same uterine cavity
Number of subjects: 20
Study: 7975845

Group type: EXPERIMENTAL
Intervention: Killed leishmanial promastigotes plus BCG
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BCG alone
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Killed leishmanial promastigotes alone
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 2644335

Group type: EXPERIMENTAL
Intervention: Fluoxetine (ProzacR, Lilly) for 8 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCA)
Number of subjects: 76
Study: 1119588

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 94
Study: 31913830

Group type: EXPERIMENTAL
Intervention: Multimodal curriculum including asynchronous video on communication skills and direct patient feedback from the Communication Assessment Tool (CAT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group received the curriculum at the clerkship's end
Number of subjects: 64
Study: 28476553

Group type: EXPERIMENTAL
Intervention: e‐cigarettes (complete switch)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: e‐cigarettes (partial switch)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Complete cessation of tobacco and nicotine products
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Smoking reduction (general)
Number of subjects: 105
Study: 25391889

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23533318

Group type: EXPERIMENTAL
Intervention: Isoniazid (36 months daily)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 196
Study: 21831926

Group type: COMPARATOR
Intervention: Stay active care only (group 1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Stay active care and muscle stretching (group 2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Stay active care, muscle stretching and manual therapy (group 3)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Stay active care, muscle stretching, manual therapy and steroid injections (group 4)
Number of subjects: 160
Study: 18298230

Group type: EXPERIMENTAL
Intervention: Integrated cognitive‐behavioral therapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: 12‐step facilitation therapy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Life stressors
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Chronic stress levels
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Acute stress events
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Interaction of self-efficacy and life stress
Number of subjects: 113
Study: 17038946

Group type: EXPERIMENTAL
Intervention: Polyester collagen-coated vascular patch
Number of subjects: 315

Group type: COMPARATOR
Intervention: Direct closure
Number of subjects: 315
Study: 12850905

Group type: EXPERIMENTAL
Intervention: Structured aftercare (SA) programme
Number of subjects: 77

Group type: COMPARATOR
Intervention: Unstructured aftercare (UA) of crisis counselling
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both SA and UA
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pretreatment additional substance use
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analyses
Number of subjects: 77
Study: 10368454

Group type: EXPERIMENTAL
Intervention: Treatment of rickets
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Echocardiographic studies before treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Echocardiographic studies after treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Echocardiographic studies in group III
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (10 healthy infants)
Number of subjects: 27
Study: 8763050

Group type: EXPERIMENTAL
Intervention: Minaprine (200 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1988266

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6645209

Group type: EXPERIMENTAL
Intervention: Chlorothiazide
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 7
Study: 30615587

Group type: EXPERIMENTAL
Intervention: Advanced practice providers (nurse practitioners and physician assistants)
Number of subjects: 9052
Study: 28992721

Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Synthetic cartilage implant
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 202
Study: 26301086

Group type: EXPERIMENTAL
Intervention: Neuro-Emotional Technique (NET)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 24035770

Group type: EXPERIMENTAL
Intervention: 5-day regimen of antibiotics after catheter exchange
Number of subjects: 61

Group type: COMPARATOR
Intervention: 10-day regimen of antibiotics with catheter retention
Number of subjects: 61
Study: 21118681

Group type: EXPERIMENTAL
Intervention: Acarbose 50mg three times a day, titrated to 100mg three times a day after one month
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Acarbose after 7 months of therapy
Number of subjects: 96
Study: 20344882

Group type: EXPERIMENTAL
Intervention: Radio Electric Asymmetric Treatment (REAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Es-Citalopram
Number of subjects: 0
Study: 18157200

Group type: COMPARATOR
Intervention: Ventolin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salamol (new)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salamol (used)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All inhalers (Ventolin, Salamol new, Salamol used)
Number of subjects: 12
Study: 15628696

Group type: EXPERIMENTAL
Intervention: 25 mg sKET
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 mg sKET
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8